GlassScriptPhysician profile
Addison M Collins
NPI 1548722242
$3,949.38
in general payments reported to CMS, 2019-2025
20 companies · $802 in 2025
The $802 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $674 · 2022: $854 · 2023: $1,001 · 2024: $619 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.65 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,288.42 | 2021-2025 | |
| Amgen INC. | $367.12 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $318.19 | 2022-2024 | Sotyktu |
| Allergan, INC. | $275.66 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $221.19 | 2021-2025 | |
| Genzyme Corporation | $200.41 | 2021-2025 | |
| Merz North America, INC. | $156.98 | 2025 | |
| Lilly USA, LLC | $146.20 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $137.94 | 2023-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $137.68 | 2023 | Ilumya |
| Kyowa Kirin, INC. | $114.54 | 2021-2025 | Poteligeo |
| Janssen Biotech, INC. | $113.56 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $98.88 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $79.38 | 2022-2024 | |
| Pfizer INC. | $74.61 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $61.50 | 2021-2023 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.49 | 2023-2025 | Spevigo |
| Genentech USA, INC. | $44.55 | 2021-2025 | Xolair |
| Incyte Corporation | $42.52 | 2021-2024 | Opzelura |
| Blueprint Medicines Corporation | $19.56 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Addison Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.